In addition, changes in expression of canonical tumor-suppressor genes such as BRCA1, BRCA2 and TP53 as well as oncogenes like BRAF, EGFR, KRAS, MET and MYC were assessed (Figure 2F). This evidence concerns the gene BRCA2 and neoplasm.